Association of Baseline Low-Density Lipoprotein Cholesterol and Percentage Low-Density Lipoprotein Cholesterol Reduction With Statins, Ezetimibe, and PCSK9 Inhibition

IMPORTANCE: Low-density lipoprotein cholesterol (LDL-C) is an important modifiable risk factor for atherosclerotic cardiovascular disease. It is unclear whether the percentage LDL-C lowering with pharmacotherapies differs on the basis of baseline LDL-C levels. OBJECTIVE: To evaluate the association...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:JAMA Cardiol
Hlavní autoři: Marcusa, Daniel P., Giugliano, Robert P., Park, Jeong-Gun, de Lemos, James A., Cannon, Christopher P., Sabatine, Marc S.
Médium: Artigo
Jazyk:Inglês
Vydáno: American Medical Association 2020
Témata:
Brief Report
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7666429/
https://ncbi.nlm.nih.gov/pubmed/33185670
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamacardio.2020.6184
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky